Recent news on Octreotide Acetate

Novartis licences lead cancer candidate from Antisoma  -  Apr 23, 2007
In-PharmaTechnologist.com,If approved, AS1404 will add to its current arsenal of anticancer treatments: Femara (letrozole), Glivec (imatinib), Sandostatin LAR (octreotide acetate)

Ambrilia and Mallinckrodt Announce IND Filing for Phase III ...  -  Mar 14, 2007
PipelineReview.com (press release),The original Octreotide product is commercialized as Sandostatin®LAR (octreotide acetate for injectable suspension, a registered trademark and product of

Ambrilia Announces Further Distribution Partnerships for Europe ...  -  Dec 5, 2006
CCNMatthews (press release),The original product is commercialized as Sandostatin ® LAR T(octreotide acetate for injectable suspension, a registered trademark of Novartis

Ambrilia Announces Further Distribution Partnerships for Europe ...  -  Dec 5, 2006
Market Wire (press release)The original product is commercialized as Sandostatin®LAR T(octreotide acetate for injectable suspension, a registered trademark of Novartis Pharmaceuticals

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional